US policymakers evaluate strategic risks of rising Chinese biotech innovation and out-licensing

China's rapid growth in biotech innovation and record-breaking out-licensing deals are triggering a strategic review in Washington regarding supply-chain dependencies and national security. The shift reflects growing US concern over the intersection of pharmaceutical competitiveness and broader technological decoupling.